AI assistant
Qualigen Therapeutics, Inc. — Director's Dealing 2016
Feb 24, 2016
35251_dirs_2016-02-24_6cdaad4a-6382-4ccc-b7ea-3f05e4ff5c8b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RITTER PHARMACEUTICALS INC (RTTR)
CIK: 0001460702
Period of Report: 2016-02-22
Reporting Person: Ritter Ira E. (Director, Exec. Chairman, CSO, 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-02-22 | Common Stock | P | 6250 | $1.60 | Acquired | 6250 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 817272 | Indirect |
Footnotes
F1: The shares are held in a retirement plan trust of which the reporting person and his spouse are trustees. The reporting person's spouse and the revocable trust of the reporting person and his spouse are beneficiaries of the retirement plan trust. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F2: As a managing partner of Stonehenge Partners LLC, the reporting person may be deemed the beneficial owner of these shares. The reporting person expressly disclaims beneficial ownership over these shares except to the extent of his pecuniary interest therein.